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Several forms of depression are unique to women because
of their apparent association with changes in gonadal hor-
mones, which in turn modulate neuroregulatory systems
associated with mood and behavior. This review examines
the evaluation and treatment of depression that occurs
premenstrually, postpartum, or in the perimenopause on
the basis of current literature. The serotonergic antide-
pressants consistently show efficacy for severe premen-
strual syndromes (PMSs) and premenstrual dysphoric dis-
order (PMDD), and are the first-line treatment for these
disorders. The use of antidepressants for postpartum
depression is compromised by concerns for effects in the
infants of breast-feeding mothers, but increasing evidence
suggests the relative safety of the antidepressant medica-
tions, and the risk calculation should be made on an indi-
vidual basis. Estradiol may be effective for postpartum
depression and for moderate-to-severe major depression
in the perimenopause. In spite of its frequent use, proges-
terone is not effective for the mood and behavioral symp-
toms of PMS/PMDD, postpartum depression, or peri-
menopausal depressive symptoms.
Dialogues Clin Neurosci. 2002;4:177-191.
pproximately 20% of women experience an
episode of major depression, a rate that is twice that of
men.
1 The period of greatest vulnerability for women
appears to be the childbearing years, with the initial
onset of depression most likely to occur between the
ages of 25 and 44.
2 Several forms of depression are
unique to women because of their apparent association
with changes in reproductive hormones: premenstrual
dysphorias, including premenstrual syndromes (PMSs)
and premenstrual dysphoric disorder (PMDD), post-
partum depression (PPD), and depression in the peri-
menopausal period.The link among these depressive
disorders appears to be a sensitivity to normal shifts in
gonadal hormones,which affect neuroregulatory systems
that play a role in affective disorders.
3,4 Such shifts occur
during the menstrual cycle, in pregnancy and postpar-
tum, and with ovarian aging in the years leading to the
menopause.
Historically, depression has been underrecognized and
undertreated. Until recently, diagnostic criteria were
imprecise, clinical trials of purported treatments for
menstrually related depressions were lacking or poorly
done,and treatment options were generally unsupported
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Selected abbreviations and acronyms
ACTH adrenocorticotropic hormone
GnRH gonadotropin-releasing hormone
HRT hormone replacement therapy
5-HT 5-hydroxytryptamine (serotonin)
m-CPP m-chlorophenylpiperazine
OC oral contraceptive
PMDD premenstrual dysphoric disorder
PMS premenstrual syndrome
PPD postpartum depression
SSRI selective serotonin reuptake inhibitor
by scientific data. Over the last two decades, consider-
able scientific research has focused on the depressions
unique to women.This review examines the evaluation
and treatment of depression that occurs premenstrually,
postpartum, and in the perimenopause based on the 
current clinical literature.
Premenstrual dysphorias
Of the depressive disorders that affect only women,
PMSs are the most extensively studied. Severe PMS is
a chronic mood disorder that continues for many years
in reproductive-age women.
5 The etiology remains
unconfirmed. Moderate-to-severe forms of the syn-
drome result in diminished functioning and impaired
relationships that cannot be dismissed as trivial.The
Diagnostic and Statistical Manual for Mental Disorders, 4th
ed (DSM-IV) provides specific diagnostic criteria for
severe dysphoric PMS termed PMDD.
6
Prevalence
Survey studies indicate that up to 40% of menstruating
women experience some difficulty with premenstrual
symptoms.
7,8 When premenstrual distress is dominated
by emotional symptoms such as irritability, nervous-
ness,tension,and depressed mood,it is a powerful pre-
dictor of treatment-seeking behavior.In a recent com-
munity-based study,22% of menstruating women rated
moderate-to-severe premenstrual distress on an analog
measure of distress; this subjective distress was highly
correlated with each of the impairment variables,occu-
pation,leisure,partner,and friends.
9 Other studies show
that approximately 3% to 10% of reproductive-age
women met the specific criteria for PMDD.
10,11
Depression and PMS/PMDD
By definition, PMDD is a severe and dysphoric form 
of PMS. Symptoms of irritability, emotional hypersen-
sitivity,increased anxiety and food cravings,sleep diffi-
culties,and decreased concentration characterize PMDD
as well as depression, particularly atypical depression.
A lifetime history of depression ranges from about
20% to 76% in samples of women diagnosed for PMS
or PMDD,
12,13 with the higher rates substantially greater
than the lifetime prevalence of about 20% for major
depression in the female population of this age-group.
1
A family history of depressive illness is common in
women with PMS/PMDD.
5Women who seek treatment
for premenstrual symptoms frequently have other
emotional disorders, most commonly depressive dis-
oders, substance abuse, or anxiety. Conversely, women
who have mood disorders frequently experience wors-
ening of symptoms premenstrually.
14
In spite of these observable similarities, increasing 
evidence suggests that PMS/PMDD is not a simple 
variant of depression, but a distinct disorder. While
depressive symptoms characterize a substantial number
of women with severe perimenstrual distress, there is
also a sizeable group of women who do not suffer from
either depression or anxiety symptoms, but experience
severe or moderate perimenstrual distress with symp-
toms of irritability, nervousness, and tension.
9 On the
basis of epidemiologic findings, the researchers posited
that the features of irritability and tension irrespective
of the presence of depressive symptoms may form the
core symptoms of the disorder,a premise also advanced
by Eriksson, on the basis of results of antidepressant
treatment studies.
15,16 Data from epidemiologically based
twin studies indicated that the degree to which premen-
strual symptoms shared generic and environmental risk
factors with major depression was modest, a possible
indication that there is no close etiologic relationship
between the two disorders.
17 The evidence that severe
PMS/PMDD responds much more robustly to seroton-
ergic antidepressants than to other antidepressants that
are clearly effective for depressive disorders suggests dif-
ferences in underlying mechanisms.There is also empir-
ical evidence that a good response of PMS/PMDD
patients to serotonergic antidepressants is not explained
by depressive symptoms or a history of depression.
18,19
The rapid response of several days rather than several
weeks of PMS patients to selective serotonin reuptakeinhibitors (SSRIs), the efficacy of SSRIs at low doses,
and the efficacy of other serotonin agonists, including
fenfluramine
20 and buspirone,
21 which are not effective
for depression, all suggest that the underlying mecha-
nisms of severe PMS/PMDD differ from other depres-
sive disorders.
Evaluation
The diagnosis of premenstrual dysphoria, PMS, or
PMDD is made primarily on the basis of the symp-
tom pattern and the exclusion of other possible diag-
noses.The essential elements are confirmation of the
expected relationship of the symptoms to the men-
strual cycle, ie, that the symptoms occur premen-
strually and remit with menses; that the symptoms
are distressing and warrant treatment, ie, that the
symptoms impair usual functioning; and that the
symptoms are not due to another physical or mental
disorder. These elements are incorporated in the
diagnostic criteria for PMDD, which, in addition,
requires at least 5 of 11 specified symptoms that are
severe premenstrually and remit with menses.
6 It is
underscored that the symptom pattern, rather than
specific symptoms or the number of symptoms,
defines the disorder.
For a PMS/PMDD diagnosis, it is essential to confirm
the symptom pattern for two to three menstrual cycles
with prospective daily symptom ratings maintained by
the patient, especially if the symptoms are mild. Less
than half the women who report PMS provide daily
symptom reports that corroborate their retrospective
reports,
22 which are less reliable when symptoms are
not consistent and severe.
23
The major consideration after identifying the symp-
tom pattern is whether the condition is purely PMS/
PMDD or a premenstrual exacerbation of other psy-
chiatric problems or medical conditions. Premens-
trual exacerbation of symptoms may occur in other
conditions such as asthma,
24,25 migraine,
26 seizure dis-
orders,
27 alcohol intake,
28,29 depression,
14 and schizo-
phrenia.
30 There is no laboratory test that identifies
PMS/PMDD, and such tests are useful only if there are
other questions that might be answered. PMS and
PMDD are based on regular menstrual cycles within
the normal range of 22 to 35 days, and patients with
irregular cycling should be examined for other condi-
tions. Standard hematology and blood chemistry pro-
files are conducted to confirm general good health.A
thorough examination includes a review of current
and past psychiatric status, particularly mood and anx-
iety disorders that are commonly associated with
PMS/PMDD.A gynecologic examination is important
to rule out problems such as endometriosis, which
might account for the symptoms.
Serotonergic antidepressants
The serotonergic antidepressants,particularly the SSRIs,
appear to be the treatment of choice for severe PMS and
PMDD at this time.Modulating serotonergic function is
consistent with the dominant theoretical view that the
normal gonadal steroid fluctuations of the menstrual
cycle trigger an abnormal serotonergic response in vul-
nerable women.Indications of abnormalities in markers
of serotonergic transmission in women with severe PMS
include evidence of a lowered platelet imipramine bind-
ing (a peripheral marker of serotonin [5-hydroxytrypt-
amine, 5-HT] function) in the luteal phase,
31 decreased
platelet 5-HT content and 5-HT uptake during the luteal
phase,
32,33 and significantly decreased whole blood 5-HT
levels premenstrually.
34 PMS patients showed a lower 
5-HT response to tryptophan (a 5-HT precursor) during
the luteal phase compared with the follicular or mid-
luteal phases.
35 Challenge tests depleting tryptophan pro-
voked PMS symptoms,
36 while tryptophan supplemen-
tation relieved PMS symptoms in open-label treatment.
37
Following administration of the serotonin-releasing fen-
fluramine, the women with PMDD had a significantly
blunted prolactin response compared with the normal
controls.
38 Fenfluramine administered to PMS subjects
improved depressed mood and food cravings.
20
Administration of the serotonin agonist m-chlorophenyl-
piperazine (m-CPP) showed improvement of PMS
symptoms in the luteal phase and a blunted response to
cortisol and adrenocorticotropic hormone (ACTH) in
both the follicular and luteal phases of the PMS subjects
compared with normal controls.
39 Although existing
information does not indicate a causal relationship
between serotonin and PMS, the data suggest involve-
ment of the serotonergic system in this disorder.
A meta-analysis of randomized controlled trials of
SSRIs in treatment of PMS/PMDD concluded that these
drugs were an effective first-line therapy,with the over-
all standard mean difference in favor of SSRIs equiva-
lent to an odds ratio of 6.91.
40 Efficacy has been clearly
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179shown for fluoxetine,
41-46 sertraline,
18,47-50 paroxetine,
51
citalopram,
52 venlafaxine,
53 and clomipramine.
54,55 Open-
label studies showed that nefazodone
56 and fluvoxam-
ine
57 also had response frequencies in PMS treatment
similar to those in the placebo-controlled studies of
SSRIs. The only medication with Food and Drug
Administration (FDA) approval for treatment of
PMDD are fluoxetine and sertraline.
In all reports of SSRI and other serotonergic antide-
pressant treatments for PMS/PMDD,the effective doses
have remained at the low end of the dose range.An ade-
quate trial of a serotonergic antidepressant is at least
two menstrual cycles with a third cycle if there is partial
response.If a patient has an insufficient response or con-
tinuing side effects with an initial SSRI, another SSRI
can be tried.
58 Side effects are common with the onset of
treatment, but are usually transient and disappear dur-
ing the first treatment cycle. The most common side
effects include headache, nausea, insomnia, fatigue or
lethargy, diarrhea, decreased concentration, and dizzi-
ness. Decreased libido is also a common side effect of
SSRI treatment, although the few published reports of
PMS patients identified a relatively low incidence of
decreased sexual interest or reduced orgasm of 10% to
12%.
18,53 In contrast,the frequency of less sexual arousal
reported by women in depression studies ranged from
32% (sertraline) to 40% (paroxetine).
59 Whether there
is a true difference between PMS and major depression
patients with respect to this side effect is not known,but
the PMS/PMDD reports clearly are from acute treat-
ment trials,do not represent a systematic assessment of
sexual function,and may not represent experience with
longer maintenance treatment.
Luteal phase dosing
The use of medication only in the symptomatic luteal
phase of the menstrual cycle is of particular interest in
PMS/PMDD because of the cyclic pattern of the symp-
toms,which includes a clear symptom-free interval each
month, and the rapid response of these patients to
SSRIs.A number of preliminary studies examined luteal
phase dosing regimens of SSRIs and consistently report-
ed efficacy.
48-50,52,60,61Two large multicenter trials reported
efficacy of fluoxetine
62 and sertraline
13 administered for
the last 2 weeks of the menstrual cycle.As with daily
dosing, the mean doses remained low and the medica-
tions were well tolerated.No studies to date have report-
ed discontinuation symptoms with luteal phase dosing.
Although several reports suggested superiority of luteal
phase dosing over daily dosing, none were designed or
sufficiently powered to answer this question.Overall,the
studies indicate that luteal phase dosing is effective for
clearly diagnosed PMS/PMDD;previous daily treatment
with an SSRI is not required; response is usually at the
low end of the dose range; side effects are similar to
those seen in continuous dosing; and discontinuation
symptoms do not appear to be a problem in the luteal
phase dosing regimens.
Other antidepressants
The antidepressant response in PMS/PMDD appears to
be associated with potent serotonergic activity and is not
a general antidepressant effect. Other antidepressants,
which are clearly effective for major depression,such as
desipramine (a tricyclic noradrenergic antidepressant),
18
buproprion (with weak inhibition of both serotonin and
norepinephrine reuptake),
45 and maprotoline (a selec-
tive noradrenaline reuptake inhibitor),
51 were no more
effective than the placebo in PMS treatment.
Long-term treatment of PMS/PMDD
All published studies of treatment efficacy for
PMS/PMDD are based on acute treatment of 2 to 3
months’ duration.Anecdotal reports and several small
pilot investigations
63-66 suggest that PMS symptoms
return within several months if medication is stopped.It
also appears that untreated symptoms do not resolve
spontaneously,as may occur in depression,but continue
for many years, based on information from clinical tri-
als, which report that the duration of the disorder is in
the range of 8 to 10 years prior to treatment. Well-
designed,long-term maintenance studies have not been
conducted for this disorder,but these observations sug-
gest that long-term maintenance treatment may be
appropriate for patients with severe PMS/PMDD, par-
ticularly if they experience a rapid return of symptoms
after responding to medication.
Insufficient response to serotonergic antidepressants
The overall response of PMS/PMDD patients to SSRIs
is approximately 60% in controlled trials,but up to 40%
may not have sufficient response. No strong predictors
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19An expert consensus
group recommended the common clinical practice of
shifting to a second SSRI when the patient has an insuf-
ficient response or is intolerant to the initial SSRI.
58
Augmenting an SSRI with other medications has not
been tested in PMS/PMDD studies.Switching to anoth-
er class of medication that has shown efficacy for
PMS/PMDD,such as anxiolytics or gonadotropin-releas-
ing hormone (GnRH) agonists, is suggested, but there
are no data that indicate whether nonresponders to an
SSRI will respond to another class of medication.
Nonresponse may also be due to other comorbid disor-
ders. A thorough review of the diagnosis and adjust-
ments of the premenstrual doses of medication for the
primary disorder should be considered before pursuing
other treatments for PMS.
Other treatments 
Hormonal treatment
Hormonal treatments for PMS/PMDD are not support-
ed by consistent scientific information in spite of 
evidence of hormonal involvement in the disorder.
67
GnRH agonists, such as depot leuprolide
68,69 and
intranasal buserelin,
70,71 effectively reduce PMS symp-
toms, but are of limited use because of the risks associ-
ated with low estrogen levels, particularly osteoporosis,
and these medications are viewed as appropriate only as
a diagnostic tool or for patients who do not respond to
other treatments. Results of preliminary investigations
of add-back therapy using low-dose estrogen and prog-
esterone in conjunction with a GnRH agonist are incon-
sistent and do not yet definitively indicate that this is a
safe as well as effective approach for long-term treat-
ment.
72-74 Limited data indicate that tibolone (a selective
estrogen enzyme modulator) administered with a
GnRH agonist in PMS treatment protects against the
bone loss observed with GnRH agonists and does not
reduce the therapeutic effect of the agonist.
75
There are few randomized,placebo-controlled studies of
oral contraceptives (OCs) as a treatment for severe PMS
or PMDD,and no consistent scientific evidence of their
efficacy for the disorder.
76,77 A triphasic OC was more
effective than placebo only for physical symptoms of
breast pain and bloating.
76A recent trial of an OC con-
taining a new progestin,an analog of spironolactone with
antimineralocorticoid and antiandrogenic activity,showed
a consistent reduction of both physical and behavioral
PMS symptoms including dysphoric mood,but addition-
al studies with sufficient statistical power are needed.
78
From a clinical perspective, OCs are widely viewed as
both improving and worsening PMS symptoms.
Combination OCs have both estrogenic and progesta-
tional effects that vary considerably among the more
than 40 compounds available in the USA. Relative
absorption of the hormones, peripheral conversion, the
degree of follicular development in the placebo interval,
individual susceptibility to monophasic or triphasic 
formulations, and side effects have large variations
among women and are not well understood in relation
to PMS. Moreover, OCs can have side effects of water
retention, bloating, appetite changes, and depressed
mood, which are also PMS symptoms. Some studies
showed that OC users had fewer PMS symptoms than
nonusers overall,
79 but other investigations found few
symptom differences between the two groups and 
no difference with respect to mood changes.
80 In sum,
there is little empirical support or guidance for OCs as
a treatment for PMS/PMDD,
81 although it is reasonable
to try OCs, particularly when contraception is also
required. If mood symptoms are predominant and 
persist, a serotonergic antidepressant is considered the
first-line therapy.
Estrogen therapy with dose regimens sufficient to 
suppress ovulation significantly decreased the dysphor-
ic mood and physical symptoms of PMS.
82-84 However,
estrogen must be cycled with progesterone to reduce the
risk of uterine cancer, and the extent to which exoge-
nous progesterone results in return of PMS symptoms
remains unclear. Progesterone treatment of PMS was
advocated for many years,but numerous studies,includ-
ing three large randomized controlled trials, failed to
show improvement significantly greater than placebo for
the mood and behavioral symptoms of PMS.
85-87
Anxiolytics
Alprazolam and buspirone showed modest efficacy 
for PMS in some studies,
87-91 but not others.
92,93 The 
well-known risk of dependence with alprazolam must be
considered,and this medication should be tried only when
the patient has symptoms clearly limited to the luteal
phase (so that the medication is stopped for at least 2
weeks in each cycle) and no history of substance abuse.
These medications offer an alternative to antidepressants,
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antidepressants respond to these anxiolytics is not known.
Nonpharmacologic approaches 
Numerous nonpharmacologic approaches have been
advocated for PMS, but few are supported by solid
empirical evidence.
94 A large study of calcium supple-
mentation (600 mg twice daily) for PMS reduced pre-
menstrual depression, fatigue, edema, and pain signifi-
cantly more than the placebo. However, the severity of
the dysphoric mood symptoms was not indicated, and
further information is required to determine the effica-
cy of this treatment for premenstrual dysphorias.
95
A meta-analysis showed that vitamin B6 was about twice
as likely as placebo to improve PMS symptoms overall,
with an odds ratio for improvement in depressive symp-
toms of 1.69, but the researchers concluded that the
quality of the studies was too poor to have confidence in
the results.
96There was no significant dose response,indi-
cating that the amount of vitamin B6 did not affect
improvement, and reports of peripheral neuropathies
with doses exceeding 200 mg preclude the use of mega-
doses.
96
Several reports of cognitive therapies show improve-
ment of premenstrual symptoms.
94 Other complemen-
tary and alternative therapies showed no convincing evi-
dence of efficacy for PMS in a review of randomized
controlled trials (dietary supplements, 13 trials; herbal
medicines, 7 trials; biofeedback, 2 trials; homeopathy,
relaxation,massage,reflexology,and chiropractic,1 trial
each).
97
Emerging from a long history with little understanding
and many treatments of doubtful effect, clinically sig-
nificant PMS is now recognized as a chronic disorder
that impairs functioning and personal relationships for
a sizeable number of women. Serotonergic antidepres-
sants are the first-line treatment at this time.Using these
medications only in the symptomatic luteal phase is
effective for women without other comorbid disorders.
Hormonal treatments for PMS are not supported by
consistent scientific data on efficacy and safety, in spite
of evidence of hormonal involvement in the disorder.
Perimenopause
When women are in their forties, anovulation becomes
more frequent and menstrual cycles are altered in length
and frequency.
98This reproductive transition extends for
2 to 8 years before the menopause, which is defined as
the point where there was no menstrual bleeding for 12
months.
99 The mean duration of the perimenopausal
transition is about 5 years;the onset occurs between the
ages of 39 and 51 years for 95% of women.
100 Although
cycle irregularity is the traditional clinical marker for
perimenopause, it is increasingly clear that hormonal
changes and distressing menopausal symptoms such as
hot flashes can occur before observed cycle changes,
which are an unreliable indicator of the perimeno-
pause.
101
Prevalence of depression
Among the most controversial issues in the transition to
menopause is its association with depression.Whether
there is an association, what the causes are, and how
such depression should be treated are questions that
continue to have no definitive answers. Epidemiologic
studies based on self-report of menopausal status and
dysphoric mood have consistently shown that most post-
menopausal respondents do not report high rates of
depressive symptoms and that reported depressive
symptoms were not related to menopause per se but to
other health problems,
102-104 and suggest that menopause
does not cause depressive illness.
105 The National
Comorbidity Study reported 30-day estimates of major
depression of 5.0% and lifetime estimates of 21.8% for
women aged 45 to 54 years, slightly lower than the esti-
mates for the 35- to 44-year age-group, which had the
highest rates of depression.
106 However, the rates of
recurrent depression were highest in the 45- to 54-year
age-group when compared with older women.
107 The
Massachusetts Health Study
102 found that in the cohort
of women aged 45 to 55 years at baseline prior depres-
sion was the variable most predictive of subsequent
depression,based on self-report of depressive symptoms
using the Center for Epidemiologic Studies–Depression
(CES-D) scale.
108 The chance of a recurrence of depres-
sion is high (50% after a first episode, 70% after two
episodes,and 90% after three episodes)
109 and may coin-
cide with the perimenopausal years.
Most cross-sectional studies suggest that women in the
40- to 55-year age-group are more likely to report
depressive symptoms than pre- and postmenopausal
women.In the current Study of Women’s Health Across
the Nation (SWAN), 40.5% of the sample of women
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within the past 2 weeks.
110 Dennerstein et al defined per-
imenopausal status from bleeding patterns and report-
ed that 38% of late perimenopausal women reported
depressive symptoms in the previous 2 weeks compared
to 26% of the premenopausal and 28% of the post-
menopausal women.
111 Bosworth et al reported that
28.9% of women aged 45 to 54 years had a high level of
depressive symptoms based on an abbreviated CES-D
scale, but found no association between the depressive
symptoms and menopausal stage defined by the
women’s perceptions.
112 Soares et al identified 28.7% of
women aged 40 to 58 years attending a menopause clin-
ic as meeting DSM-IV criteria for depressive disorders.
113
While all these studies suggest an increased prevalence
of depressive symptoms and possibly depressive illness
in the transition to menopause,whether these depressive
symptoms are associated with hormonal fluctuations or
changes that characterize the transition to menopause
remains unclear.
Estrogen as an antidepressant
Estrogen treatment is widely believed to improve
depressive symptoms in menopausal women,
114-118 but
study results are inconclusive because of large varia-
tions in study design and measures, hormonal status
and diagnosis of the subjects,the estrogen compound,
dose, and duration of use, and failure to find an effect
greater than the placebo response.
119-122
Burt et al
123 identified six studies that included peri-
menopausal women for estrogen treatment of depres-
sive symptoms. Only two studies were placebo-con-
trolled; only one of these showed significant
improvement with estradiol compared with placebo
after 4 months of treatment,but the treatment advan-
tage over placebo was not sustained after 12 months
of treatment.
124 In an uncontrolled study of women
judged to be depressed or not depressed on the basis
of the Beck Depression Inventory,only the group that
was not depressed responded to standard replacement
doses (0.3–0.625 mg/day) of conju-gated estrogen.
125
Pharmacologic doses of estradiol (5–25 mg/day)
showed improvement greater than placebo in women
diagnosed with depressive disorders
126 and in a study
of postmenopausal women with scores signifying men-
tal distress (1–4 mg/day).
127 Conclusions cannot be
drawn from the conflicting results of these studies,
which are limited by designs that do not clearly iden-
tify essential variables,such as menopausal status and
diagnosis of depression,and also lack comparability in
the form and dose of estrogen treatment.
Two recent well-designed studies found 17β-estradiol
to be effective for depression in perimenopausal
women. Both studies clearly diagnosed depression,
endocrinologically defined perimenopausal status and
administered transdermal 17β-estradiol (the major cir-
culating estrogen in women) using randomized,place-
bo-controlled, double-blind designs and showed that
estrogen may be an effective treatment for major or
minor depression in perimenopausal women.Soares et
al
128 reported remission of depression in 68% of the
estradiol group compared with 20% of the placebo
group after 12 weeks. Schmidt et al
129 showed a full or
partial response for 80% of the estradiol group com-
pared with 22% of the placebo group after 6 weeks of
estradiol.A progestin added at 7 weeks did not negate
improvement with one exception of worsening of early
morning waking.Both studies indicated that the effect
of estradiol on mood was independent of hot flashes—
an important finding that suggests that the improve-
ment of depressed mood with estrogen treatment was
not simply a result of improving hot flashes.Both stud-
ies identified a rapid onset of antidepressant response
in perimenopausal depression. However, the brief
duration of the progestin use may be inadequate to
determine whether long-term progesterone use
reduces the beneficial estradiol effect on mood.
116
Further studies are needed to confirm these positive
findings and determine long-term effects of estradiol
treatment.
Estrogen administration throughout the cycle may be
more effective than the standard OC regimen for
decreasing depressive symptoms in perimenopausal
women. Blümel et al compared a standard OC (20 µg
ethinyl estradiol and 150 mg desogestrel for 21 days
followed by placebo for 7 days) with the same OC fol-
lowed by only 2 days of placebo and 5 days of 10 µg
ethinyl estradiol in a randomized trial.
130 Depressive,
vasomotor,and somatic symptoms and sexual function
improved significantly more in the group with estro-
gen continued throughout the cycle.The results were
interpreted by the researchers to indicate that increas-
ing the days with estrogen in women using OCs res-
timulated estrogen receptors and improved cerebral
neurochemistry.
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The SSRIs (fluoxetine, paroxetine, and sertraline) and
other serotonergic antidepressants such as venlafaxine,
nefazodone, and clomipramine are currently viewed as
the first-line treatment for most depressive disorders
because of extensive data supporting their efficacy, the
minimal need for dose titration,and generally favorable
side-effect profiles.
58 However,there is growing evidence
of gender differences and effects of menstrual status in
treatment response and tolerability to SSRIs.Women
with chronic major depression were more likely to
respond to sertraline compared with men, who were
more likely to respond to the tricyclic antidepressant,
imipramine.
131 Menstrual status affected this response,
with premenopausal women significantly more likely to
respond to the serotonergic than a tricyclic antidepres-
sant,while the postmenopausal women responded sim-
ilarly to both medications.The postmenopausal women
who were taking imipramine also had significantly lower
attrition rates than premenopausal women. Similar
results were observed in a comparison of fluoxetine with
maprotiline.
132
Other observations of postmenopausal women identified
an interaction between estrogen status and antidepres-
sant therapies:women who were using estrogen replace-
ment therapy and received fluoxetine had a greater anti-
depressant response than the women who received only
fluoxetine
133; similarly, older depressed women who
received both estrogen and sertraline responded better
than those who received only sertraline.
134Another trial
of fluoxetine in depressed menopausal women failed to
find any effect of estrogen therapy,but the subjects were
younger (≥45 years of age) and menopausal status was
determined only by age,limiting interpretation and com-
parisons of the results.
135 Overall,these preliminary find-
ings suggest that menstrual status is an important con-
sideration in selecting an antidepressant for women,and
that the estrogen status (which differs in pre-,peri-,and
postmenopausal women) may be associated with the
response to antidepressants.
Management of depression in perimenopausal women
Current consensus guidelines for treatment of depression
in perimenopausal women recommend an antidepressant
for severe depression.
58 Data indicate that an SSRI may
be preferred to a tricyclic antidepressant for women who
are not postmenopausal. For women with previous
episodes of depression, the general guideline is to pre-
scribe the antidepressant used in the previous episode if
the patient had a satisfactory response.
Transdermal estradiol (0.05–0.10 mg/day) may be of ben-
efit for perimenopausal women with major or minor
depression,based on preliminary but consistent findings
of two new studies.
128,129
Minor mood symptoms associated with the perimenopause
are also improved with estrogen therapy.
116 A progestin
must also be prescribed for women with a uterus and may
reduce the improvement of depressed mood in some
women.Estrogen therapy is generally contraindicated for
women with breast cancer, any potentially estrogen-
dependent malignancy, active liver disease, and active
thrombosis.Speroff et al indicate close surveillance for
women with seizure disorders,familial hyperlipidemias,
and migraine headaches.
136 Other considerations include
a history of breast disease,history of stroke,myocardial
infarction or thrombosis,and active gall bladder disease
or gallstones.
The estradiol dose of hormone replacement therapy
(HRT) does not suppress ovulation or provide contracep-
tion for perimenopausal women, who continue to be at
risk of pregnancy until the menopause.
137 For contracep-
tive protection and for estrogen-related symptoms such as
hot flashes,an OC with estrogen rather than HRT may be
preferred for perimenopausal women.However,there is
no evidence at this time that OCs effectively treat major
or minor depression in perimenopausal women.Recent
studies suggested that reducing the placebo interval of
OCs and extending estradiol through the cycle improved
depressive symptoms,but these findings do not extend to
women diagnosed with depressive illness.The association
of cardiovascular events with estrogen is dose-related and
the current low-dose OCs (<50 µg ethinyl estradiol) can
be used by perimenopausal women with normal blood
pressure.
137 Smokers over age 35 should not use OCs.
A frequently asked question is whether estrogen and anti-
depressant therapies can be combined. The strongest
rationale for using both medications is the known bene-
fits of each.In addition to its psychotropic effect,estradi-
ol reduces menopause-related hot flashes,improves vagi-
nal dryness, is protective against bone loss, which may
result in osteoporosis,and may be protective against car-
diovascular disease.
137 Recent evidence indicates that
estrogen can produce an antidepressant response in per-
imenopausal women with major or minor depression.
128,129
Pharmacological aspects
184Antidepressants are clearly effective for dysphoric mood.
Although preliminary findings have suggested that the
combined use of HRT and serotonergic antidepressants
enhanced the antidepressant response,these observations
pertained to elderly depressed women and cannot be gen-
eralized to perimenopausal women.There are no studies
of combined estrogen and antidepressant therapies in
women identified as perimenopausal.
To assess perimenopausal depression, the pattern and
severity of the depressive symptoms should be deter-
mined. Perimenopausal status is suggested by the pres-
ence of vasomotor symptoms such as hot flashes or
irregular menstrual cycles, although it is entirely possi-
ble that a perimenopausal woman has neither, particu-
larly in the early stages of the menopausal transition.
Careful physical examination and medical history should
be obtained to determine other coexisting conditions,
previous experience of any depressive disorder, the
onset of the depressive symptoms in conjunction with
menstrual cycle changes,and to identify risk factors and
contraindications for estrogen therapy.A follicle-stimu-
lating hormone (FSH) level greater than 20 IU/L is a
hormonal marker of the perimenopause,but single mea-
sures are considered unreliable because of sporadic fol-
licular activity and competence. The decline in mean
estrogen levels occurs primarily in the year before
menopause,
138 although there is considerable individual
variability. Burger et al recently reported that mean
estrogen levels started to decrease about 2 years before
the final menstrual period, but fell substantially only in
the year before the final menses with the most rapid
decrease around the time of the final menstrual period.
139
Recognition that the perimenopause can extend over a
number of years and that the hormonal shifts that occur
in this transition may be associated with depressive
symptoms is important for patient care.However,scien-
tific data to guide treatment of depression in the peri-
menopause are limited and inconclusive.Estrogen ther-
apy may be helpful for major or minor depression as
well as for depressive symptoms linked to the meno-
pause. OCs containing estrogen are another possible
option for perimenopausal women, who still require
contraceptive protection, but there is no consistent evi-
dence at this time of their antidepressant effects.The
hormone doses of OCs are considerably higher than
those of HRT,but only the HRT dose levels of estrogen
have shown antidepressant effects in perimenopausal
women at this time. Serotonergic antidepressants are
clearly effective for depressive illness, and are now 
widely considered the first-line treatment for moderate-
to-severe depressive illness or a repeated episode of
depression in perimenopausal women.
Postpartum depression
The months following childbirth have been recognized
throughout history as a period of increased risk of
depression for vulnerable women, although diagnostic
criteria have emerged only in recent decades,and there
are few well-designed controlled studies of treatment
efficacy. Two defining characteristics of PPD are its
occurrence at a time of large hormonal shifts and its high
likelihood of recurrence with subsequent pregnancies.
Prevalence
PPD is a nonpsychotic depression that meets the 
diagnostic criteria for major depression and occurs with-
in several months of delivery as defined in the DSM-IV.
6
The point-prevalence of PPD within 6 to 9 weeks of
delivery is about 12%.
140,141 Postpartum psychosis is
uncommon, but potentially lethal to the woman or the
infant, and occurs in 1 to 2 per 1000 women following
childbirth, with onset usually within 2 to 4 weeks of
delivery.
142 Mood lability,or “baby blues”within the ini-
tial days following delivery is very common,with esti-
mates up to 80% for brief periods of symptoms such as
tearfulness, fatigue, and insomnia that occur within the
first 2 weeks of childbirth,peaking at about 5 days post-
partum.
143
It was long believed that women were at decreased
risk of depressive disorders during pregnancy,and few 
studies examined associations between depression 
during pregnancy and the postpartum period.However,
studies show that depression can increase steadily
from the second trimester of pregnancy to 9 weeks
postpartum,
140,143 with little difference in prevalence
(9% in the second trimester;12% postpartum) or even
greater prevalence during pregnancy than postpar-
tum.
144,145 Data also indicate that the depressive symp-
toms differ when compared during pregnancy and in
early and later postpartum periods,corroborating both
the occurrence of depressive symptoms during preg-
nancy and identifying differing vulnerabilities to
depression throughout pregnancy and the postpartum
period.
146
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A recent review indicated that the increased risk was
25% for women with a history of depression, 50% for
women with previous PPD, and 75% for women with
depression during the current pregnancy.
58 Twenty-nine
percent of women diagnosed with late luteal phase dis-
order and 43% of women diagnosed with PMS had
experienced PPD, suggesting possible association with
premenstrual syndromes.
147,148 Other risk factors for PPD
include poor social support and chronic stressors.
149
Treatment of postpartum depression
Reported treatments for PPD include antidepressants,
hormones, and psychotherapy, but there is a paucity of
well-designed controlled studies, samples are small and
there are no definitive conclusions.
Antidepressants
Sertonergic antidepressants with reported efficacy for
PPD include fluoxetine in double-blind study,
150 and ser-
traline, venlafaxine, and fluvoxamine in open studies.
151-
153 Results in the sertraline study suggested that response
is swift (by 2 weeks) and at low doses,but these findings
were not supported in another retrospective record
review.
154 The many antidepressants available are clear-
ly effective for depression but are generally unstudied
for PPD.Other considerations in the selection of an anti-
depressant are the patient’s tolerability of side effects
and the response to a previously prescribed antidepres-
sant. For women with previous episodes of depression,
the general guideline is to prescribe the antidepressant
used in the previous episode if the patient had a satis-
factory response.
A major concern about drug therapy for breast-feeding
mothers is the effect of medication on the infant.
155 In
small studies, amitriptyline, nortriptyline, desipramine,
clomipramine, imipramine, sertraline, fluvoxamine, and
paroxetine were not detected in quantifiable amounts in
infant plasma and all infants were thriving.
156-161 The
results are encouraging,but cannot be generalized to all
infants exposed to these medications.
Because of the high risk of repeated PPD,the question of
prophylactic treatment is important but unanswered.In
the only controlled study of an antidepressant adminis-
tered as a prophylactic,the tricyclic antidepressant,nor-
triptyline, initiated immediately postpartum in nonde-
pressed women at risk of a subsequent PPD,was not bet-
ter than placebo;25% of the women in each group had
a recurrence of PPD.
162
Hormone treatments
Sublingual 17β-estradiol (1 mg,3 to 8 times/day to achieve
a serum concentration of 400 pmol/L) in open treatment
for 8 weeks resulted in rapid and significant improvement
for women with severe PPD.
163The women had very low
serum estradiol concentrations at the pretreatment base-
line (mean = 21.7 pg/mL),but whether the low estradiol
levels differed from those of asymptomatic postpartum
women could not be determined in the absence of a con-
trol group. Women with postpartum psychosis also
responded to 17β-estradiol treatment in a similar study
conducted by the same researchers.
164
Transdermal 17β-estradiol (delivery of 200 µg/day for 6
months) was significantly better than placebo for PPD,
meeting criteria for major depressive disorder.
165 The
response occurred in the first month of treatment and was
sustained for the 6 months of the randomized, double-
blind study.The effect on symptoms of a progestin added
after 3 months was not reported;endometrial curettage
at the end of treatment showed endometrial changes (sic)
in three women,which resolved on follow-up.
A very small open pilot study administered estrogen
immediately after delivery to prevent recurrent PPD.
166A
much lower relapse rate than expected in the ensuing
year (9% versus an expected 35% to 60% without pro-
phylaxis) suggested the utility of estrogen for high-risk
women and supported the hypothesis that PPD may be
triggered by rapid changes in the levels of estradiol in vul-
nerable women.However,possible problems with high-
dose estrogen therapy such as the need to administer
coagulants and the interference of estrogen with breast
milk are not yet answered.
167
Evidence does not support progesterone treatment for
PPD.
168 Nor is there scientific evidence to support the
prophylactic use of progesterone to prevent the recur-
rence of PPD.A randomized controlled trial of norethi-
sterone enanthate given within hours of delivery report-
ed an increased risk of developing PPD.
169
Psychotherapy
Although there is increasing evidence that antide-
pressants are relatively safe, concerns for possible
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ports psychotherapy as the treatment for PPD in
breast-feeding mothers.Evaluation of women mild-to-
moderate major depression, who were randomized to
interpersonal psychotherapy (IPT) or wait-list condi-
tion for 12 weeks demonstrated significantly greater
improvement in PPD and social adjustment for the
psychotherapy group.
170 Another study reported that
fluoxetine and six sessions of cognitive behavioral
therapy were each effective for minor and major
depression occurring in the first 6 to 8 weeks postpar-
tum, but also found no advantage to receiving both
treatment modalities.
171
Management
The most serious problem in the management of PPD 
is its underrecognition and undertreatment. Maternal
depression can impair mother–infant bonding and
affect cognitive and emotional development.
172Women
with a history of PPD or another mood disorder
require close observation and prompt treatment of
depressive symptoms. However, detection of possible
PPD has been poor in routine clinical evaluation.
173
Identification of possible PPD significantly increased
when a simple screening scale was used (6% vs 35%).
173
Another study showed that the rate of diagnosis of
PPD increased from about 4% to 11% following the
implementation of a universal screening of postpartum
women.
141 A brief screening scale (eg, the 10-item
Edinburgh Postnatal Depression Scale)
171 appears to be
an essential tool for identifying women who may have
clinically significant depression in the postpartum period.
Consensus guidelines indicate that the first-line treat-
ment of PPD is antidepressants whether or not the
mother is breast-feeding.
58 Although case-series com-
parisons have consistently reported no clinically sig-
nificant differences in the infants of mothers taking or
not taking antidepressant medications,relatively small
numbers of women and their infants have been stud-
ied, and the findings are not sufficient to generalize to
all infants at this time.Thus, it remains important to
consider the risk/benefit equation for each woman in
selecting treatment for PPD.
Conclusions
Serotonergic antidepressants are generally the first-line
treatment for menstrually related depressions—PPD,
premenstrual dysphorias, and depression in the peri-
menopause—using regimens that are proven for major
depression.While there is increasing evidence that the
reproductive hormones are involved in these disorders,
knowledge of their use as effective and safe treatments
is still limited. Preliminary studies indicate that estro-
gen replacement therapy is effective for major and
minor depression in perimenopausal women with or
without a history of depression.Pilot data suggest that
estradiol may be effective for severe PPD.
Progesterone is clearly not effective for depressive
symptoms in PMS/PMDD, the postpartum or peri-
menopause. Safety concerns for medications during
pregnancy and breast-feeding point to psychotherapy
as the treatment for PPD, but the risk calculation of
each treatment modality should be made on an indi-
vidual basis. No one treatment entirely fits each of
these complex disorders with their still-heterogeneous
populations, and a one-fits-all treatment approach is
not possible.Nonetheless,understanding knowledge of
the causes and treatments of women’s depressions is
increasing, and many women with these disorders can
obtain relief with effective medical treatment. ❏
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El tratamiento de la depresión asociada con
el ciclo menstrual: disforia premenstrual,
depresión postparto y depresión perimeno-
páusica.
Algunas formas de depresión son específicas de la
mujer dada su aparente asociación con cambios en
las hormonas gonadales, las que a su vez modulan
los sistemas neurorreguladores asociados con el
ánimo y la conducta. Esta revisión examina la eva-
luación y tratamiento de la depresión que ocurre
en el período premenstrual, en el postparto o en la
perimenopausia de acuerdo con la literatura actual.
Los antidepresivos serotoninérgicos muestran una
clara eficacia en algunos síndromes premenstruales
severos (SPM) y en el trastorno disfórico premens-
trual (TDP), y constituyen el tratamiento de prime-
ra línea para estos trastornos. El empleo de anti-
depresivos para la depresión postparto es discutido
debido a los efectos que provoca en los niños de
madres que están lactando, pero hay una crecien-
te evidencia que sugiere que la seguridad relativa
de los medicamentos antidepresivos y el cálculo del
riesgo debe hacerse caso a caso. El estradiol puede
ser eficaz en la depresión postparto y en la depre-
sión mayor moderada a grave en la perimenopau-
sia. A pesar de su uso frecuente, la progesterona no
es eficaz para los síntomas anímicos y conductuales
del SPM o del TDP, la depresión postparto o los sín-
tomas depresivos perimenopáusicos. 
Traitement de la dépression associée au
cycle menstruel : dysphorie prémenstruelle,
dépression du post-partum, et périméno-
pause
Plusieurs formes de dépression propres aux femmes
seraient dues à leur apparente association aux
variations des hormones gonadiques, lesquelles en
retour modulent les systèmes neuromédiateurs liés
à l’humeur et au comportement. Cette revue de la
littérature actuelle fait le point sur l’évaluation et
le traitement de la dépression tant prémenstruelle
que survenant au cours du post-partum ou de la
périménopause. Les antidépresseurs sérotoniner-
giques ont une efficacité constante sur les syn-
dromes prémenstruels sévères (SPM) et sur les
désordres dysphoriques prémenstruels (DDPM), et
représentent le traitement de première intention
de ces troubles. La crainte des effets des antidé-
presseurs chez les enfants de mères qui allaitent
fait obstacle à leur utilisation au cours de la dépres-
sion du post-partum, mais de plus en plus d'argu-
ments suggèrent la relative sécurité des médica-
ments antidépresseurs, et l’évaluation du risque
devrait être faite au cas par cas. L’estradiol pourrait
être efficace dans la dépression du post-partum et
la dépression majeure modérée à sévère de la péri-
ménopause. Malgré son utilisation fréquente, la
progestérone n’est efficace ni sur l’humeur et les
symptômes comportementaux des SPM/DDPM et
de la dépression du post-partum, ni sur les symp-
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